{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:13:57Z","timestamp":1788372837395,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"DOI":"10.1007\/s11307-026-02135-3","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:24:26Z","timestamp":1788369866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[64Cu]CuCl2 as a Novel Metabolic Marker of Progression and Survival in Muscle-Invasive Bladder Cancer"],"prefix":"10.1007","author":[{"given":"Francesco","family":"Fiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bottoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Boitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ugolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Magistrali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Massollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Iacozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Campodonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Luigi Augusto","family":"Negro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Panareo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Timossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Vallome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Introini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3932-1330","authenticated-orcid":false,"given":"Arnoldo","family":"Piccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2135_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijsu.2018.02.049","volume":"52","author":"J Chen","year":"2018","unstructured":"Chen J, Zhang H, Sun G et al (2018) Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: a systematic review and meta-analysis. Int J Surg 52:214\u2013220","journal-title":"Int J Surg"},{"key":"2135_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"1980","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD (1980) Bladder cancer: a review. JAMA 324:1980\u20131991","journal-title":"JAMA"},{"key":"2135_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013465","journal-title":"Eur Urol"},{"key":"2135_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216255","volume":"14","author":"MS Wettstein","year":"2019","unstructured":"Wettstein MS, Rooprai JK, Pazhepurackel C et al (2019) Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: does the current quality of evidence justify definitive conclusions? PLoS ONE 14:e0216255","journal-title":"PLoS ONE"},{"key":"2135_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA et al (2023) Bladder cancer. Nat Rev Dis Primers 9:58","journal-title":"Nat Rev Dis Primers"},{"key":"2135_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/14737140.2020.1784011","volume":"20","author":"RK Jain","year":"2020","unstructured":"Jain RK, Sonpavde G (2020) Neoadjuvant therapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 20:603\u2013614","journal-title":"Expert Rev Anticancer Ther"},{"key":"2135_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681","journal-title":"Lancet Oncol"},{"key":"2135_CR8","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni GS, Hermanns T, Wei Y et al (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35:2299\u20132305","journal-title":"J Clin Oncol"},{"key":"2135_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A et al (2024) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85:17\u201331","journal-title":"Eur Urol"},{"key":"2135_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L (2024) Advances in diagnosis and treatment of bladder cancer. BMJ 384:e076743","journal-title":"BMJ"},{"key":"2135_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3857\/roj.2015.33.4.294","volume":"33","author":"SJ Byun","year":"2015","unstructured":"Byun SJ, Kim JH, Oh YK, Kim BH (2015) Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. Radiat Oncol J 33:294\u2013300","journal-title":"Radiat Oncol J"},{"key":"2135_CR12","doi-asserted-by":"publisher","first-page":"356.e311","DOI":"10.1016\/j.urolonc.2023.04.017","volume":"41","author":"R Chung","year":"2023","unstructured":"Chung R, Moran GW, Movassaghi M et al (2023) Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy. Urol Oncol 41:356.e311-356.e318","journal-title":"Urol Oncol"},{"key":"2135_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/bs.acc.2021.07.005","volume":"107","author":"F Wilson","year":"2022","unstructured":"Wilson F, Joseph N, Choudhury A (2022) Biomarkers in muscle invasive bladder cancer. Adv Clin Chem 107:265\u2013297","journal-title":"Adv Clin Chem"},{"key":"2135_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2174\/1389557516666160512151202","volume":"20","author":"M Boegemann","year":"2020","unstructured":"Boegemann M, Krabbe LM (2020) Prognostic implications of immunohistochemical biomarkers in non-muscle-invasive blad cancer and muscle-invasive bladder cancer. Mini Rev Med Chem 20:1133\u20131152","journal-title":"Mini Rev Med Chem"},{"key":"2135_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1124\/mol.113.085068","volume":"83","author":"KD Ivy","year":"2013","unstructured":"Ivy KD, Kaplan JH (2013) A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol 83:1237\u20131246","journal-title":"Mol Pharmacol"},{"key":"2135_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00775-017-1467-y","volume":"22","author":"MC Akerfeldt","year":"2017","unstructured":"Akerfeldt MC, Tran CM, Shen C et al (2017) Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. J Biol Inorg Chem 22:765\u2013774","journal-title":"J Biol Inorg Chem"},{"key":"2135_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.lungcan.2014.04.005","volume":"85","author":"ES Kim","year":"2014","unstructured":"Kim ES, Tang X, Peterson DR et al (2014) Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer 85:88\u201393","journal-title":"Lung Cancer"},{"key":"2135_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101626","volume":"29","author":"X Wang","year":"2023","unstructured":"Wang X, Lou Q, Fan T et al (2023) Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma. Transl Oncol 29:101626","journal-title":"Transl Oncol"},{"key":"2135_CR19","first-page":"355","volume":"19","author":"V Montazeri","year":"2020","unstructured":"Montazeri V, Ghahremani MH, Montazeri H et al (2020) A preliminary study of NER and MMR pathways involved in chemotherapy response in bladder transitional cell carcinoma: impact on progression-free survival. Iran J Pharm Res 19:355\u2013365","journal-title":"Iran J Pharm Res"},{"key":"2135_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/iub.50","volume":"60","author":"D Horn","year":"2008","unstructured":"Horn D, Barrientos A (2008) Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life 60:421\u2013429","journal-title":"IUBMB Life"},{"key":"2135_CR21","doi-asserted-by":"publisher","first-page":"19507","DOI":"10.1073\/pnas.1318431110","volume":"110","author":"S Ishida","year":"2013","unstructured":"Ishida S, Andreux P, Poitry-Yamate C et al (2013) Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A 110:19507\u201319512","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2135_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118893","volume":"1868","author":"VC Shanbhag","year":"2021","unstructured":"Shanbhag VC, Gudekar N, Jasmer K et al (2021) Copper metabolism as a unique vulnerability in cancer. Biochim Biophys Acta Mol Cell Res 1868:118893","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2135_CR23","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.7150\/thno.29840","volume":"8","author":"A Parmar","year":"2018","unstructured":"Parmar A, Pascali G, Voli F et al (2018) In vivo [64Cu]CuCl2 PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis. Theranostics 8:5645\u20135659","journal-title":"Theranostics"},{"key":"2135_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11307-022-01769-3","volume":"25","author":"F Fiz","year":"2023","unstructured":"Fiz F, Bottoni G, Ugolini M et al (2023) Diagnostic and dosimetry features of [64Cu]CuCl2 in high-grade paediatric infiltrative gliomas. Mol Imaging Biol 25:391\u2013400","journal-title":"Mol Imaging Biol"},{"key":"2135_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2967\/jnumed.117.195628","volume":"59","author":"A Piccardo","year":"2018","unstructured":"Piccardo A, Paparo F, Puntoni M et al (2018) 64CuCl2 PET\/CT in prostate cancer relapse. J Nucl Med 59:444\u2013451","journal-title":"J Nucl Med"},{"key":"2135_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.23736\/S1824-4785.20.03277-X","volume":"64","author":"A Piccardo","year":"2020","unstructured":"Piccardo A, Ugolini M, Righi S et al (2020) Copper, PET\/CT and prostate cancer: a systematic review of the literature. Q J Nucl Med Mol Imaging 64:382\u2013392","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2135_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2967\/jnumed.124.267474","volume":"65","author":"A Piccardo","year":"2024","unstructured":"Piccardo A, Bottoni G, Puppo C et al (2024) Role of 64CuCl2 PET\/CT in detecting and staging muscle-invasive bladder cancer: comparison with contrast-enhanced CT and 18F-FDG PET\/CT. J Nucl Med 65:1357\u20131363","journal-title":"J Nucl Med"},{"key":"2135_CR28","first-page":"159","volume":"31","author":"P Panichelli","year":"2016","unstructured":"Panichelli P, Villano C, Cistaro A et al (2016) Imaging of brain tumors with copper-64 chloride: early experience and results. Cancer Biother Radiopharm 31:159\u2013167","journal-title":"Cancer Biother Radiopharm"},{"key":"2135_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0969-8051(96)00157-6","volume":"24","author":"DW McCarthy","year":"1997","unstructured":"McCarthy DW, Shefer RE, Klinkowstein RE et al (1997) Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 24:35\u201343","journal-title":"Nucl Med Biol"},{"key":"2135_CR30","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 78:4786\u20134789","journal-title":"Cancer Res"},{"key":"2135_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2135_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/978-3-030-42618-7_19","volume":"216","author":"J Becker","year":"2020","unstructured":"Becker J, Schwarzenb\u00f6ck SM, Krause BJ (2020) FDG PET hybrid imaging. Recent Results Cancer Res 216:625\u2013667","journal-title":"Recent Results Cancer Res"},{"key":"2135_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211\u2013218","journal-title":"Trends Biochem Sci"},{"key":"2135_CR34","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1113\/JP278810","volume":"599","author":"P Vaupel","year":"2021","unstructured":"Vaupel P, Multhoff G (2021) Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol 599:1745\u20131757","journal-title":"J Physiol"},{"key":"2135_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/RLU.0000000000004185","volume":"47","author":"F Fiz","year":"2022","unstructured":"Fiz F, Bini F, Gabriele E et al (2022) Role of dynamic parameters of 18F-DOPA PET\/CT in pediatric gliomas. Clin Nucl Med 47:517\u2013524","journal-title":"Clin Nucl Med"},{"key":"2135_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/cac2.70005","volume":"45","author":"D Shan","year":"2025","unstructured":"Shan D, Song J, Ren Y et al (2025) Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities. Cancer Commun (Lond) 45:577\u2013607","journal-title":"Cancer Commun (Lond)"},{"key":"2135_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216157","volume":"561","author":"X Wang","year":"2023","unstructured":"Wang X, Zhou M, Liu Y, Si Z (2023) Cope with copper: from copper linked mechanisms to copper-based clinical cancer therapies. Cancer Lett 561:216157","journal-title":"Cancer Lett"},{"key":"2135_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57538-7","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Yang D, Yu HF et al (2025) Copper is essential for cyclin B1-mediated CDK1 activation. Nat Commun 16:2288","journal-title":"Nat Commun"},{"key":"2135_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W et al (2023) Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat 68:100938","journal-title":"Drug Resist Updat"},{"key":"2135_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y et al (2024) Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat 73:101059","journal-title":"Drug Resist Updat"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02135-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:24:28Z","timestamp":1788369868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02135-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":40,"alternative-id":["2135"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02135-3","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}